Ocular Prosthesis Market Trends, Challenges and Opportunities to 2030: A Projected $2.3 Billion Landscape
December 24, 2024 05:57 ET
|
Research and Markets
Dublin, Dec. 24, 2024 (GLOBE NEWSWIRE) -- The "Ocular Prosthesis - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Ocular...
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer
December 23, 2024 10:59 ET
|
Research and Markets
Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Aesthetic Ophthalmology Devices - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
December 19, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 19, 2024 06:38 ET
|
Ocugen
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular...
Macular Edema Global Clinical Trials Review 2024 - Coverage of Disease Clinical Trials by Region, Country, Phase, Trial Status, End Points Status and Sponsor Type
December 19, 2024 04:33 ET
|
Research and Markets
Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Macular Edema - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report...
Eye Care Associates Moves to Nextech
December 17, 2024 09:00 ET
|
Nextech Systems, Inc.
Eye Care Associates of Northeastern Ohio has selected Nextech’s ophthalmic platform to automate workflows and improve the patient care experience.
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
December 17, 2024 06:00 ET
|
Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
December 11, 2024 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”),...
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
December 11, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Iantrek Announces Peer-Reviewed Publication Highlighting 12-Month Safety and Effectiveness Results for its Bio-Interventional Uveoscleral Outflow Technology in Open-Angle Glaucoma Patients
December 10, 2024 08:00 ET
|
Iantrek, Inc.
White Plains, Dec. 10, 2024 (GLOBE NEWSWIRE) -- White Plains, NY – December 10, 2024 – Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and...